{
  "id": 8018643,
  "title": "Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.",
  "url": "https://urgent.news/2026/09/17/wall-street-sees-a-huge-rebound-for-viking-therapeutics-heres-why-8018643",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-17T11:05:00.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/wall-street-sees-huge-rebound-viking-therapeutics-heres-why-analysts-are-so-optimistic"
  },
  "original_language": "en",
  "account": null,
  "summary": "Key PointsVK2735's dual formulation and rapid weight loss onset could be key differentiators provided the phase 3 trials are successful.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Motley Fool",
        "title": "Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic.",
        "url": "https://urgent.news/2026/09/17/wall-street-sees-a-huge-rebound-for-viking-therapeutics-heres-why",
        "published": "2026-09-17T10:45:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}